AbbVie executives outlined growth plans across immunology, oncology, and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies, and a business development approach focused on long-term strategic assets. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in Q4 and plans further combination-therapy data. AbbVie also anticipates data later this year from Phase III studies of lutikizumab and RINVOQ in hidradenitis suppurativa (HS), and is advancing the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results. Management reiterated its outlook for high-single-digit annual revenue growth through the decade and expects annual R&D spending to approach $10 billion this year, having invested about $20 billion in roughly 30 transactions over